ADC Therapeutics SA (ADCT)

Compare

2.0450

+0.1550

(+8.22%)

As of 3:31:16 PM EST. Market Open.

$ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

PR Newswire 5 days ago

ADCT
+8.22%
$ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma$

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma (FL) were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66th American Society o

PR Newswire 7 days ago

ADCT
+8.22%
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

PR Newswire 10 days ago

ADCT
+8.22%
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024 (each, a "Grant").

PR Newswire 13 days ago

ADCT
+8.22%
BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ...

BerGenBio ASA (FRA:7BG0) navigates challenges with FDA fast-track designation and robust cash reserves, while addressing leadership changes and program discontinuations.

GuruFocus.com last month

ADCT
+8.22%
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations

ADC Therapeutics ( NYSE:ADCT ) Third Quarter 2024 Results Key Financial Results Revenue: US$18.5m (up 27% from 3Q...

Simply Wall St. last month

ADCT
+8.22%
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside – Here’s Why Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The company's lead asset, Zynlonta (loncastuximab tesirine-Ipyl), is a CD19-directed ADC with a pyrrolobenzodiazepine (PBD) payload. The drug received accelerated FDA

Benzinga last month

ADCT
+8.22%
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -16.67% and 1.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ADCT
+8.22%
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.

PR Newswire last month

ADCT
+8.22%
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25% and 5.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

FOLD

ADCT
+8.22%
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced independent, investigator-initiated study abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 7-10, 2024.

PR Newswire last month

ADCT
+8.22%
ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November:

PR Newswire last month

ADCT
+8.22%
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.

Zacks last month

ADCT
+8.22%
AGIO
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates.

PR Newswire last month

ADCT
+8.22%
Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT)

Key Insights Given the large stake in the stock by institutions, ADC Therapeutics' stock price might be vulnerable to...

Simply Wall St. last month

ADCT
+8.22%
ADC Therapeutics to Present at Upcoming Investor Conferences

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Date: September 9, 2024Presentation Time: 7:00 a.m. ETFormat: Virtual Fireside Chat Speaker: Ameet Mallik, Chief Executive Officer 10th Cantor Global Healthcare Conference 2024 Date: Se

GlobeNewswire 3 months ago

ADCT
+8.22%
ADC Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ADC Therapeutics ( NYSE:ADCT ) Second Quarter 2024 Results Key Financial Results Revenue: US$17.4m (down 9.7% from 2Q...

Simply Wall St. 4 months ago

ADCT
+8.22%
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 13.64% and 8.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

ADCT
+8.22%
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 trial expected before year-end 2024 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commer

GlobeNewswire 4 months ago

ADCT
+8.22%
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -11.57% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

VRTX

ADCT
+8.22%

Performance Overview

Return	ADCT	S&P 500
YTD	+23.19%	+27.50%
1-Year	+28.62%	+28.87%
3-Year	-89.74%	+29.13%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ADC Therapeutics SA (ADCT)

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ...

ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics to Present at November Investor Conferences

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT)

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates

Performance Overview